Whitehawk Therapeutics, Inc.

WHWK

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Avoro Capital Advisors OrbiMed Advisors

AI Signal

AI analyst context — unlock full analysis

Position Trend

Feb 17, 2026

$10.1M

1 fund

Mar 16, 2026

$6.9M

1 fund

-32% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Avoro Capital AdvisorsNEWMar 16, 2026

Shares: 2,849,402Value: $6.9M

# Signal Note: Avoro Capital Initiates WHWK Position Avoro's $6.9M entry into Whitehawk signals conviction in the company's lead program, a potency-enhanced GLP-1 receptor agonist (WH0002) for obesity/diabetes, which entered Phase 2 dosing in 2024. The biotech specialist's investment likely reflects confidence in differentiated pharmacology versus crowded GLP-1 space, with near-term catalysts including Phase 2 efficacy/safety readouts expected 2025-2026. This represents a meaningful validation from a focused life sciences investor typically deploying capital in clinical-stage companies with defined inflection points.

OrbiMed AdvisorsNEW

More WHWK Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

APLS2 funds RNA2 funds ARGX2 funds ASND2 funds PTCT2 funds UTHR2 funds GPCR2 funds KRYS

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: OrbiMed Initiates $10.1M Position in Whitehawk Therapeutics OrbiMed's entry into WHWK (4.2M shares, ~4.7% stake) signals conviction in the company's precision oncology platform, likely driven by upcoming clinical catalysts or data readouts in its lead programs targeting difficult-to-treat cancers. As a mega-fund with deep biotech expertise, this validates WHWK's scientific approach but warrants monitoring of near-term trial updates and cash runway to assess risk/reward at current valuation.